Glucotrack Expands Board with New Addition
RUTHERFORD, N.J. — Glucotrack, Inc. (NASDAQ: GCTK), a pioneering medical device company dedicated to innovations for those with diabetes, is thrilled to announce the election of Victoria E. Carr-Brendel, PhD, to its Board of Directors as of May 22. This strategic move is aimed at bolstering the company’s efforts in bringing advanced blood glucose monitoring technologies to market.
In a statement, Paul V. Goode, PhD, the President and CEO of Glucotrack, expressed excitement about Dr. Carr-Brendel joining the team. He noted her extensive experience in medical devices and innovative technologies, emphasizing how her insights will be crucial as Glucotrack progresses with its continuous blood glucose monitoring (CBGM) solutions through essential clinical phases.
Dr. Carr-Brendel's Expertise
Dr. Carr-Brendel is not new to leadership in the medical field. Currently, she serves on the board of Vicarious Surgical Inc. (NYSE: RBOT) since January 2023. Her prior experience includes high-ranking positions such as President and Group Vice President of Cochlear Implants at Sonova Group from 2018 to 2024. Moreover, she has been at the helm of JenaValve Technology, where she focused on innovative heart valve solutions.
Her professional journey also spans time at Boston Scientific, a notable leader in the medical device industry. Here, she played a critical role in the company's key acquisition, which greatly enhanced their capabilities in interventional radiology. Dr. Carr-Brendel’s commitment to innovation is reflected in her impressive portfolio of over forty patents and her foundational roles in research and development with companies like Dexcom and Baxter Healthcare.
Vision for the Future
Expressing her thoughts on joining Glucotrack, Dr. Carr-Brendel stated, "Joining Glucotrack’s Board of Directors is an honor. Their cutting-edge CBGM technology has unparalleled potential in addressing the vital needs of diabetes care while improving automated insulin delivery processes. I eagerly look forward to aiding the company in achieving its pivotal clinical and strategic milestones.”
The Innovative CBGM Technology
Glucotrack’s CBGM is designed to be a long-term, implantable solution that provides seamless monitoring of glucose levels over an extended period of three years. Unlike traditional systems that require wearing devices externally, this innovative approach minimizes invasiveness, allowing for a more comfortable user experience. The system gathers real-time data directly from the blood, ensuring accurate monitoring, distinct from other methods that track glucose from interstitial fluid.
Currently, the Glucotrack Continuous Blood Glucose Monitor is classified as an investigational device under U.S. law and is intended for investigational use only.
For those looking to learn more about the powerful capabilities of Glucotrack’s CBGM technology, additional information can be accessed through the company's official website.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is dedicated to the design and commercialization of innovative technologies aimed at improving the lives of those with diabetes. The company is sharply focused on bringing its long-term implantable continuous blood glucose monitoring system to fruition.
This unique CBGM solution not only promises a user-friendly experience by eliminating the need for on-body wear but also reduces the frequency of calibrations, making diabetes management simpler and more effective.
Frequently Asked Questions
1. What is the main focus of Glucotrack, Inc.?
Glucotrack, Inc. is focused on developing innovative technologies to improve diabetes care, specifically through continuous blood glucose monitoring.
2. Who is the newest member of the Board of Directors?
Dr. Victoria E. Carr-Brendel has recently been elected to Glucotrack’s Board of Directors.
3. What is unique about Glucotrack's blood glucose monitoring technology?
Glucotrack’s CBGM is implantable and requires no wearable components, offering a continuous and accurate way to monitor blood glucose levels for up to three years.
4. How will Dr. Carr-Brendel contribute to Glucotrack?
Her extensive experience in medical devices and her leadership in innovative implantable technologies will be crucial in advancing Glucotrack's offerings in diabetes management.
5. Is Glucotrack's CBGM available for public use?
No, currently, the Glucotrack Continuous Blood Glucose Monitor is an investigational device, limited to research and developmental use.
